噬菌体展示体内筛选技术及其应用进展

俞杨; 王自正

噬菌体展示体内筛选技术及其应用进展

俞杨 , 王自正

文章导航 > 国际放射医学核医学杂志 > 2008, 32 > 1: (5-8)

引用本文:

Citation:

噬菌体展示体内筛选技术及其应用进展

俞杨,
王自正^,

210006 南京, 南京医科大学附属南京第一医院南京市临床核医学中心

通讯作者: 王自正, zzwang136@yahoo.com.cn

中图分类号: R782

Phage display in vivo selection and its application

YU Yang,
WANG Zi-zheng^,

Nanjing Clinical Nuclear Medicine Center, Nanjing First Hospital Affiliatied to Nanjing Medical University, Nanjing 210006, China

Corresponding author: WANG Zi-zheng, zzwang136@yahoo.com.cn

CLC number: R782

摘要: 噬菌体展示技术是将高度多样性的多肽或蛋白展示于噬菌体衣壳蛋白表面的一项技术。这一技术将展示分子的基因型和表型联系在一起,极大地方便了多肽或蛋白分子的功能性筛选。从噬菌体展示文库中筛选出的多肽或蛋白具有高度的特异性和极强的亲和力,在生物医学基础研究和临床诊断治疗中具有重要的应用价值。随着噬菌体展示技术的不断发展,已将其用于活体的体内筛选。体内筛选技术发挥了高通量筛选的特点,能够在活体水平研究血管表面的分子表达状况,分析不同器官血管表面分子的表达差异,从而为临床靶向性诊断和治疗提供实验依据。
- 噬菌体展示 /
- 肽库 /
- 体内筛选 /
- 血管异质性
Abstract: Phage display technology is a kind of method which display peptides or proteins of high diversity on the surface of phage coat proteins. This technology establish a linkage between genotype and phenotype, which makes functional screen of peptides or proteins convenient. Peptides or proteins screened from phage display library have high specificity and strong affinity, and play an important roles in basic research and clinical diagnosis and therapy. With the development of phage display, it has been used in the in vivo selection. It has characteristics of high throughput selection so that it can reveal molecular profiles and the differences of molecular profiles expressed on the vascular surface of different organs. Studies of in vivo selection can provide experimental evidences for the targeting diagnosis and therapy.
- Phage display /
- Phage library /
- In vivo selection /
- Vascular heterogeneity
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Smith GP. Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface[J]. Science, 1985, 228(4705):1315-1317.
[2]	Kehoe JW, Kay BK. Filamentous phage display in the new millennium[J]. Chem Rev, 2005, 105(11):4056-4072.
[3]	Lanner RC, Sato AK, Gorzelany J, et al. Phage display-derived peptides as therapeutic alternatives to antibodies[J]. Drug Discov Today, 2004, 9(12):525-529.
[4]	Ruoslahti E. Drug targeting to specific vascular sites[J]. Drug Discov Today, 2002, 7(22):1138-1143.
[5]	Hajitou A, Pasquallni R, Arap W. Vascular targeting:recent advances and therapeutic perspectives[J]. Trends Cardiovasc Med, 2006, 16(3):80-88.
[6]	Zurita AJ, Arap W, Pasqualini R. Maping tumor vascular diversity by screening phage display libraries[J]. J Control Release, 2003, 91(1-2):183-186.
[7]	Neri D, Bicknell R. Tumour vascular targeting[J]. Nat Rev Cancer, 2005, 5(6):436-446.
[8]	George AJ, Lee L, Pitzalis C. Isolating ligands specific for human vasculature using in vivo phage selection[J]. Trends Biotechnol, 2003, 21(5):199-203.
[9]	Landon LA, Deutscher SL. Combinatorial discovery of tumor targeting peptides using phage display[J]. J Cell Biochem, 2003, 90(3):509-517.
[10]	Liu C, Bhattacharjee G, Boisvert W, et al. In vivo interrogation of the molecular display of atherosclerotic lesion surfaces[J]. Am J Pathol, 2003, 163(5):1859-1871.
[11]	Kelly KA, Nahrendorf M, Yu AM, et al. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging[J]. Mol Imaging Biol, 2006, 8(4):201-207.
[12]	Landon LA, Zou J, Deutscher SL. Is phage display technology on target for developing peptide-based cancer drugs?[J]. Curr Drug Discov Technol, 2004, 1(2):113-132.
[13]	Trepel M, Arap W, Pasqualini R. In vivo phage display and vascular heterogeneity:implications for targeted medicine[J]. Curr Opin Chem Biol, 2002, 6(3):399-404.
[14]	Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue[J]. Nat Med, 2004, 10(6):625-632.
[15]	Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display[J]. Nat Med, 2002, 8(2):121-127.
[16]	Ruoslahti E. Vascular zip codes in angiogenesis and metastasis[J]. Biochem Soc Trans, 2004, 32(pt3):397-402.
[17]	Zurita A, Troncoso P, Cardo-Vila M, et al. Combinatorial screenings in patients:the interleukin-11 receptor as a candidate target in the progression of human prostate cancer[J]. Cancer Res, 2004, 64(2):435-439.
[18]	Essler M, Ruoslahti E. Molecular specialization of breast vaseulature:A breast-homing phage-displayed peptlde binds to aminopeptidase P in breast vasculature[J]. Proc Natl Acad Sci USA, 2002, 99(4):2252-2257.
[19]	Laakkonen P, Porkka K, Hoffman JA, et al. A tumor-homing peptide with a targeting specificity related to lymphatic vessels[J]. Nat Med, 2002, 8(7):751-755.
[20]	Laakkonen P, Akerman ME, Biliran H, et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells[J]. Proc Natl Acad Sci USA, 2004, 101(25):9381-9386.
[21]	Krag DN, Shukla GS, Shen GP, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries[J]. Cancer Res, 2006, 66(15):7724-7733.
[22]	Sokolov K, Aaron J, Hsu B, et al. Optical systems for in vivo molecular imaging of cancer[J]. Technol Cancer Res Treat, 2003, 2(6):491-504.
[23]	Denardo SJ. Combined molecular targeting for cancer therapy:a new paradigm in need of molecular imaging[J]. J Nucl Med, 2006, 47(1):4-5.
[24]	Lewis MR. Radiolabeled RGD peptides move beyond cancer:PET imaging of delayed-type hypersensitivity reaction[J]. J Nucl Med, 2005, 46(1):2-4.

[1]	阳艳丽 , 王自正 . 噬菌体展示技术在肿瘤诊断和治疗中的应用. 国际放射医学核医学杂志, 2008, 32(2): 65-68.
[2]	黄斌 , 俞杨 , 王自正 . 噬菌体展示肽库技术在肿瘤诊治研究中的应用. 国际放射医学核医学杂志, 2011, 35(4): 202-206. doi: 10.3760/cma.j.issn.1673-4114.2011.04.002
[3]	褚丽萍 , 王彦 , 王月英 , 刘金剑 , 吴红英 , 刘鉴峰 . 多肽类肺癌显像剂的制备及其初步鉴定. 国际放射医学核医学杂志, 2010, 34(3): 135-138. doi: 10.3760/cma.j.issn.1673-4114.2010.03.002
[4]	刘金剑 , 刘鉴峰 , 孟爱民 . 噬菌体展示技术在分子核医学中的应用. 国际放射医学核医学杂志, 2013, 37(6): 352-354,373. doi: 10.3760/cma.j.issn.1673-4114.2013.06.007
[5]	涂少华 , 陶嵘 , 沈江帆 . 单克隆抗体人源化技术研究进展. 国际放射医学核医学杂志, 2014, 38(5): 328-331. doi: 10.3760/cma.j.issn.1673-4114.2014.05.012
[6]	马荣政 , 王蒙 , 方纬 , 张宗耀 , 汪蕾 . 慢性血栓栓塞性肺动脉高压患者核素肺通气/灌注分布异质性的初步定量研究. 国际放射医学核医学杂志, 2020, 44(5): 291-297. doi: 10.3760/cma.j.cn121381-201902028-00021
[7]	王冉 , 张涵玥 , 韩星敏 . ¹⁸F-FDG PET/CT肿瘤内代谢异质性指数预测胃腺癌隐匿性淋巴结转移的价值. 国际放射医学核医学杂志, 2023, 47(): 1-8. doi: 10.3760/cma.j.cn121381-202303006-00378
[8]	史育红 , 谭天秩 . 血管活性肠肽受体研究现状. 国际放射医学核医学杂志, 1998, 22(4): 148-152.
[9]	王雪鹃 , 张梅颖 , 林保和 . 肿瘤血管活性肠肽受体显像. 国际放射医学核医学杂志, 2001, 25(2): 65-69.
[10]	李前伟 , 谭天秩 , 林汉 . 放射性核素标记血管活性肠肽的肿瘤受体显像. 国际放射医学核医学杂志, 1996, 20(3): 124-128.
[11]	宋进华 , 王自正 , 周云 , 刘璐 , 王峰 , 顾建平 . ¹⁸⁸Re-奥曲肽在荷瘤裸鼠体内分布的实验研究. 国际放射医学核医学杂志, 2006, 30(1): 14-16,38.

点击查看大图

计量

文章访问数: 1476
HTML全文浏览量: 104
PDF下载量: 2

噬菌体展示体内筛选技术及其应用进展

俞杨
王自正^,

通讯作者: 王自正, zzwang136@yahoo.com.cn

210006 南京, 南京医科大学附属南京第一医院南京市临床核医学中心

收稿日期: 2007-07-05

关键词:

摘要: 噬菌体展示技术是将高度多样性的多肽或蛋白展示于噬菌体衣壳蛋白表面的一项技术。这一技术将展示分子的基因型和表型联系在一起,极大地方便了多肽或蛋白分子的功能性筛选。从噬菌体展示文库中筛选出的多肽或蛋白具有高度的特异性和极强的亲和力,在生物医学基础研究和临床诊断治疗中具有重要的应用价值。随着噬菌体展示技术的不断发展,已将其用于活体的体内筛选。体内筛选技术发挥了高通量筛选的特点,能够在活体水平研究血管表面的分子表达状况,分析不同器官血管表面分子的表达差异,从而为临床靶向性诊断和治疗提供实验依据。